Background illustration for clinical trials search

Triple Negative Breast Cancer Clinical Trials

Browse 2,256 triple negative breast cancer clinical trials enrolling across the United States and Canada. Search by city or state to find one near you.

Filter
1
Active & Responsive

Observational Assessment of Skin Appearance Changes During PRX S Cosmetic Treatment in Participants With Acne-Prone Skin

for
Acne-prone Skin, Skin Disease
Location: Leawood KS, Tulsa OK
Sponsor: WiQo S.p.A.

Sex: All

Age: 18+

Code: NCT07866131

Recruiting
Active & Responsive

TRAIL-R2 and HER2 Bi-Specific Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Metastatic Breast Cancer

for
Breast Cancer, Tumor, Breast, Breast Tumor,
Location: Houston TX
Sponsor: Baylor College of Medicine

Sex: All

Age: 18 - 70+

Code: NCT06251544

Phase 1, Recruiting
Active & Responsive

Older Breast Cancer Patients: Risk for Cognitive Decline

for
Cancer, Breast, Age-related Cognitive Decline,
Location: Washington D.C. DC
Sponsor: Georgetown University

Sex: Female

Age: 60 - 70+

Code: NCT03451383

Recruiting
Active & Responsive

REC-7735 in Participants With Solid Tumors

for
Solid Tumors
Location: Fairfax VA, Grand Rapids MI, Irving TX
Sponsor: Recursion Pharmaceuticals Inc.

Sex: All

Age: 18+

Code: NCT07819136

Phase 1, Phase 2, Recruiting
Active & Responsive

Effect of Meal Timing During Adjuvant Treatment for Cancer

for
Cancer
Location: Los Angeles CA
Sponsor: Fred Hutchinson Cancer Center

Sex: All

Age: 18+

Code: NCT07524218

Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image
Active & Responsive

A Study to Identify Breast Cancer (IDBC)

for
Breast Cancer Female
Location: Calgary
Sponsor: Syantra Inc.

Sex: Female

Age: 30 - 70+

Code: NCT04495244

Recruiting
Active & Responsive

Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors

for
Somatostatin Receptor Positive, NETs, Lymphoma, Solid Tumor,
Location: Philadelphia PA, Cincinnati OH, Houston TX,
Sponsor: ITM Solucin GmbH

Sex: All

Age: 2 - 18

Code: NCT06441331

Phase 1, Recruiting
Active & Responsive

Asciminib in HER2+ Breast Cancer Brain Metastases

for
HER2+ Metastatic Breast Cancer
Location: Durham NC
Sponsor: Duke University

Sex: Female

Age: 18+

Code: NCT07136428

Phase 1, Phase 2, Recruiting
Active & Responsive

A Study to Investigate Safety and Efficacy of KB111 for the Treatment of Hailey-Hailey Disease

for
Hailey Hailey Disease, Skin Diseases, Lesion Skin
Location: Miami FL
Sponsor: Krystal Biotech, Inc.

Sex: All

Age: 12+

Code: NCT07717346

Early Phase 1, Recruiting
Active & Responsive

Remotely-Delivered Cognitive Behavioral Stress Management for Breast Cancer (R-CBSM)

for
Breast Cancer
Location: Coral Gables FL
Sponsor: University of Miami

Sex: Female

Age: 50+

Code: NCT07502352

Recruiting
Active & Responsive

Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases

for
Clear Cell Renal Cell Cancer (ccRCC),
Location: San Francisco CA
Sponsor: Kelly Fitzgerald, MD

Sex: All

Age: 18+

Code: NCT07043608

Phase 2, Recruiting
Active & Responsive

Non-inferiority Study Comparing Salvage Pelvic Radiotherapy in 25 Fractions (62.5 Gy/25) Versus 20 Fractions (52.5 Gy/20) for Recurrent Prostate Cancer After Surgery.

for
Reccurent/Metastatic Solid Tumor Disease,
Location: Quebec
Sponsor: CHU de Quebec-Universite Laval

Sex: Male

Age: 18+

Code: NCT07483658

Recruiting
Active & Responsive

Burn Pit Exposure in Veterans: A Cancer Screening Pilot Study at the Inova Saville Cancer Screening & Prevention Center

for
Cancer
Location: Fairfax VA
Sponsor: Inova Health Care Services

Sex: All

Age: 35 - 70+

Code: NCT07485322

Recruiting
Active & Responsive

The EASE Study: Randomized Trial of a Novel Approach to Addressing Fear of Progression in Advanced Cancer

for
Advanced Solid Tumor Cancer,
Location: Aurora CO, Boulder CO
Sponsor: University of Colorado, Boulder

Sex: All

Age: 18+

Code: NCT07636200

Recruiting
Active & Responsive

A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer

for
Advanced Breast Cancer, Early Breast Cancer
Location: Westbury NY, The Bronx NY, New York NY, Amsterdam NY,
Sponsor: TerSera Therapeutics LLC

Sex: Female

Age: 18 - 55

Code: NCT07310420

Phase 1, Recruiting
Active & Responsive

A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies

for
Solid Tumors
Location: Boston MA, St. Petersburg FL, Germantown TN,
Sponsor: Mirati Therapeutics Inc.

Sex: All

Age: 18+

Code: NCT07415031

Phase 2, Recruiting
Active & Responsive

Direct to Patient Minimal Risk Biospecimen and Data Collection Research

for
Healthy, Lupus, Celiac, Kidney Disease, Chronic, Dermatologic
Location: Lexington MA
Sponsor: Joined Bio

Sex: All

Age: 18 - 70+

Code: NCT07128966

Recruiting
Active & Responsive

High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer

for
Anatomic Stage IV Breast Cancer AJCC v8,
Location: Atlanta GA
Sponsor: Emory University

Sex: All

Age: 18+

Code: NCT06492759

Phase 2, Recruiting
Active & Responsive

Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer

for
HR+ HER2- Breast Cancer
Location: Tampa FL, Nashville TN, Austin TX, San Antonio TX,
Sponsor: Faeth Therapeutics

Sex: All

Age: 18+

Code: NCT07558733

Phase 1, Phase 2, Recruiting
Active & Responsive

A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement

for
FGFR2 Gene Fusion/Rearrangement, Other Solid Tumors, Adult
Location: Boston MA, New York NY, Tampa FL, Chicago IL,
Sponsor: Elevar Therapeutics

Sex: All

Age: 18+

Code: NCT07359820

Phase 2, Recruiting

What is triple negative breast cancer?

Triple negative breast cancer, or TNBC, is breast cancer whose cells test negative for estrogen receptors, progesterone receptors, and excess HER2 protein, so hormone therapy and HER2 targeted drugs do not work against it. It tends to grow faster and is more common in women who have not gone through menopause, in Black women, and in people with an inherited BRCA1 mutation, so genetic testing is recommended for everyone diagnosed. In US data, five year relative survival is about 92 percent when it is found while localized, 67 percent with regional spread, and 15 percent once it has reached distant organs. Standard treatment for early stage disease is chemotherapy combined with immunotherapy before surgery, followed by more treatment after; metastatic disease is treated with chemotherapy, immunotherapy for PD-L1 positive tumors, and antibody drug conjugates. Other breast cancers are covered on our breast cancer clinical trials page.

Types of triple negative breast cancer clinical trials

Who can participate in triple negative breast cancer clinical trials?

Is triple negative breast cancer hereditary?

Stages of triple negative breast cancer, and why they matter for trials

How to enroll in a triple negative breast cancer clinical trial